BRIEF—Nerlynx licensing deal agreed in Israel

The USA’s Puma Biotechnology has agreed a deal for Medison Pharma to seek regulatory approval for and commercialize breast cancer therapy Nerlynx (neratinib) in its native Israel.

Puma will receive upfront and milestone payments throughout the term of this agreement, as well as double-digit royalties on sales.

Puma chief executive Alan Auerbach said: “Our new agreement with Medison demonstrates our commitment to bringing Nerlynx to patients around the world while continuing to focus our commercial resources on the US market.”

Medison said it expected to receive regulatory approval in the first half of 2019.